Afatinib Recruiting Phase 2 Trials for Recurrent Lymphoma / Bladder Carcinoma / Rectal Carcinoma / Malignant Uterine Neoplasm / Plasma Cell Myeloma / Recurrent Skin Carcinoma / Recurrent Cervical Carcinoma / Solid Neoplasms / Melanoma / Lung, Carcinoma / Recurrent Uterine Corpus Carcinoma / Advanced Malignant Solid Neoplasm / Advanced Malignant Neoplasm / Recurrent Thyroid Gland Carcinoma / Recurrent Liver Carcinoma / Refractory Lymphomas / Recurrent Rectal Carcinoma / Thyroid Gland Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Plasma Cell Myeloma / Skin Carcinoma / Recurrent Gliomas / Carcinoma, Pancreatic / Carcinoma, Breast / Liver and Intrahepatic Bile Duct Carcinoma / Ovarian Carcinoma / Gliomas / Recurrent Colorectal Carcinoma / Recurrent Bladder Carcinoma / Refractory Malignant Solid Neoplasm / Head and Neck Carcinoma / Recurrent Esophageal Carcinoma / Gastric Carcinoma / Endometrial Carcinoma / Recurrent Prostate Carcinoma / Carcinoma, Colorectal / Recurrent Malignant Solid Neoplasm / Recurrent Lung Carcinoma / Colon Carcinoma / Refractory Plasma Cell Myeloma / Malignant Lymphomas / Renal Carcinoma / Recurrent Pancreatic Carcinoma / Recurrent Breast Carcinoma / Recurrent Melanoma / Recurrent Solid Neoplasm / Cervical Carcinoma / Prostate Cancer / Oesophageal Carcinoma / Refractory Malignant Neoplasm / Recurrent Gastric Carcinoma / Uterine Corpus Cancer / Recurrent Head and Neck Carcinoma / Recurrent Colon Carcinoma Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02465060NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma